Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Arati V. Rao"'
Autor:
Mark B. Geyer, Ellen K. Ritchie, Arati V. Rao, Shreya Vemuri, Jessica Flynn, Meier Hsu, Sean M. Devlin, Mikhail Roshal, Qi Gao, Madhulika Shukla, Jose M. Salcedo, Peter Maslak, Martin S. Tallman, Dan Douer, Jae H. Park
Publikováno v:
Haematologica, Vol 106, Iss 8 (2020)
Administration of pediatric-inspired chemotherapy to adults up to age 60 with acute lymphoblastic leukemia (ALL) is challenging in part due to toxicities of asparaginase as well as myelosuppression. We conducted a multicenter phase II clinical trial
Externí odkaz:
https://doaj.org/article/5b2e995adcfa4bf8893807d57ad1b9bd
Autor:
Michael Wang, Preetesh Jain, T Linda Chi, Sheree E Chen, Amy Heimberger, Shiao-Pei Weathers, Lianqing Zheng, Arati V Rao, John M Rossi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We descr
Externí odkaz:
https://doaj.org/article/b9c79dd65c64418584175a12ac69626d
Autor:
Kimberly Stegmaier, Thomas Oellerich, John C. Byrd, Scott A. Armstrong, Federica Piccioni, James S. Blachly, Alison R. Walker, Arati V. Rao, Sebastian Mohr, Björn Häupl, Amy Goodale, Amanda Robichaud, Yana Pikman, S. Haihua Chu, Linda Ross, Elizabeth S. Frank, Gabriela Alexe, Jana M. Ellegast, Anjali Cremer
IC50, pYome results in MV4-11 and MOLM14, ORF-Screen Data in MV4-11 and MOLM14 and merged hits, SNV indels and copy number alteration of MV4-11 naive and resistant cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f446a75136175200fe6b9243820699d
https://doi.org/10.1158/2159-8290.22535731
https://doi.org/10.1158/2159-8290.22535731
Autor:
Kimberly Stegmaier, Thomas Oellerich, John C. Byrd, Scott A. Armstrong, Federica Piccioni, James S. Blachly, Alison R. Walker, Arati V. Rao, Sebastian Mohr, Björn Häupl, Amy Goodale, Amanda Robichaud, Yana Pikman, S. Haihua Chu, Linda Ross, Elizabeth S. Frank, Gabriela Alexe, Jana M. Ellegast, Anjali Cremer
Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed0bced4c3c65f69e00b240c092325f0
https://doi.org/10.1158/2159-8290.c.6547933.v1
https://doi.org/10.1158/2159-8290.c.6547933.v1
Autor:
Kimberly Stegmaier, Thomas Oellerich, John C. Byrd, Scott A. Armstrong, Federica Piccioni, James S. Blachly, Alison R. Walker, Arati V. Rao, Sebastian Mohr, Björn Häupl, Amy Goodale, Amanda Robichaud, Yana Pikman, S. Haihua Chu, Linda Ross, Elizabeth S. Frank, Gabriela Alexe, Jana M. Ellegast, Anjali Cremer
Computational analysis methods for RNAseq, WES, synergy analyse, Masspec information used for phosphoproteomic studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0031104ac2b4ad7ca6be0b8eff55fa7f
https://doi.org/10.1158/2159-8290.22535734.v1
https://doi.org/10.1158/2159-8290.22535734.v1
Autor:
Kimberly Stegmaier, Thomas Oellerich, John C. Byrd, Scott A. Armstrong, Federica Piccioni, James S. Blachly, Alison R. Walker, Arati V. Rao, Sebastian Mohr, Björn Häupl, Amy Goodale, Amanda Robichaud, Yana Pikman, S. Haihua Chu, Linda Ross, Elizabeth S. Frank, Gabriela Alexe, Jana M. Ellegast, Anjali Cremer
Fig. S1: Characterization of effects of Entospletinib in AML in vitro and in vivo, Fig. S2: Genome-scale lentiviral ORFeome library screen identifies drivers of entospletinib resistance in AML.; Fig. S3: Viability analysis with increasing concentrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d05f501ea89488b1f31caab8d2352e
https://doi.org/10.1158/2159-8290.22535737
https://doi.org/10.1158/2159-8290.22535737
Autor:
William G. Blum, Arati V. Rao, Hubert Serve, Thomas Oellerich, Yang Pan, Jinfeng Liu, Lauren Long, Veerendra Munugalavadla, Mark D. Minden, Danjie Zhang, Howland E. Crosswell, Tara L. Lin, Shelley Orwick, Alice S. Mims, Bhavana Bhatnagar, James S. Blachly, John C. Byrd, Alison R. Walker
Suppl Figures 1-3, Suppl Table 1 Supplemental Figure 1. Study schema. Supplemental Figure 2. Overall survival in patients treated with ENTO + 7+3. OS is censored on the date the patient was last known to be alive (if it was not known the patient had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729ff97aaf1985b8f717f96ec31b7d7e
https://doi.org/10.1158/1078-0432.22476270
https://doi.org/10.1158/1078-0432.22476270
Autor:
William G. Blum, Arati V. Rao, Hubert Serve, Thomas Oellerich, Yang Pan, Jinfeng Liu, Lauren Long, Veerendra Munugalavadla, Mark D. Minden, Danjie Zhang, Howland E. Crosswell, Tara L. Lin, Shelley Orwick, Alice S. Mims, Bhavana Bhatnagar, James S. Blachly, John C. Byrd, Alison R. Walker
Purpose:Spleen tyrosine kinase (SYK) signaling is a proposed target in acute myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to HOXA9 and MEIS1 overexpression in preclinical studies. This trial evaluated the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68718286b612ecd09aa15987c54606bc
https://doi.org/10.1158/1078-0432.c.6529353
https://doi.org/10.1158/1078-0432.c.6529353
Autor:
Susan P. Foy, Kyle Jacoby, Daniela A. Bota, Theresa Hunter, Zheng Pan, Eric Stawiski, Yan Ma, William Lu, Songming Peng, Clifford L. Wang, Benjamin Yuen, Olivier Dalmas, Katharine Heeringa, Barbara Sennino, Andy Conroy, Michael T. Bethune, Ines Mende, William White, Monica Kukreja, Swetha Gunturu, Emily Humphrey, Adeel Hussaini, Duo An, Adam J. Litterman, Boi Bryant Quach, Alphonsus H. C. Ng, Yue Lu, Chad Smith, Katie M. Campbell, Daniel Anaya, Lindsey Skrdlant, Eva Yi-Hsuan Huang, Ventura Mendoza, Jyoti Mathur, Luke Dengler, Bhamini Purandare, Robert Moot, Michael C. Yi, Roel Funke, Alison Sibley, Todd Stallings-Schmitt, David Y. Oh, Bartosz Chmielowski, Mehrdad Abedi, Yuan Yuan, Jeffrey A. Sosman, Sylvia M. Lee, Adam J. Schoenfeld, David Baltimore, James R. Heath, Alex Franzusoff, Antoni Ribas, Arati V. Rao, Stefanie J. Mandl
Publikováno v:
Nature, vol 615, iss 7953
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells1–3. Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd691b6fa2cf73c26cc536f7201c6b0c
https://escholarship.org/uc/item/2g96s8v7
https://escholarship.org/uc/item/2g96s8v7
Autor:
Bhavana Bhatnagar, Arati V. Rao, James S. Blachly, Tara L. Lin, Alison Walker, Howland E. Crosswell, William Blum, Jinfeng Liu, Veerendra Munugalavadla, Lauren Long, Danjie Zhang, Mark D. Minden, Yang Pan, Hubert Serve, John C. Byrd, Alice S. Mims, Thomas Oellerich, Shelley Orwick
Publikováno v:
Clinical Cancer Research. 26:5852-5859
Purpose: Spleen tyrosine kinase (SYK) signaling is a proposed target in acute myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to HOXA9 and MEIS1 overexpression in preclinical studies. This trial evaluated the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c2fec3766059d9b48d163577b0fe1fe
https://doi.org/10.1158/1078-0432.ccr-20-1064
https://doi.org/10.1158/1078-0432.ccr-20-1064